Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas

Melmed, 2009, Acromegaly pathogenesis and treatment, J. Clin. Invest, 119, 3189, 10.1172/JCI39375 Theodoropoulou, 2013, Somatostatin receptors: from signaling to clinical practice, Front. Neuroendocrinol, 34, 228, 10.1016/j.yfrne.2013.07.005 Colao, 2011, Resistance to somatostatin analogs in acromegaly, Endocr. Rev, 32, 247, 10.1210/er.2010-0002 Cuevas-Ramos, 2014, Somatostatin receptor ligands and resistance to treatment in pituitary adenomas, J. Mol. Endocrinol, 52, R223, 10.1530/JME-14-0011 Giustina, 2014, Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors, Expert Opin. Investig. Drugs, 23, 1619, 10.1517/13543784.2014.942728 Giustina, 2014, Expert consensus document: a consensus on the medical treatment of acromegaly, Nat. Rev. Endocrinol, 10, 243, 10.1038/nrendo.2014.21 Taboada, 2007, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, Eur. J. Endocrinol, 156, 65, 10.1530/eje.1.02313 Taboada, 2008, Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR, Eur. J. Endocrinol, 158, 295, 10.1530/EJE-07-0562 Duran-Prado, 2009, Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors, J. Clin. Endocrinol. Metab, 94, 2634, 10.1210/jc.2008-2564 Duran-Prado, 2010, A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs, J. Clin. Endocrinol. Metab, 95, 2497, 10.1210/jc.2009-2247 Duran-Prado, 2012, The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells, Oncogene, 31, 2049, 10.1038/onc.2011.389 Puig-Domingo, 2014, The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer, PLoS ONE, 9, e85527, 10.1371/journal.pone.0085527 Neto, 2009, Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly, J. Clin. Endocrinol. Metab, 94, 1931, 10.1210/jc.2008-1826 Barlier, 1998, Prognostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas, J. Clin. Endocrinol. Metab, 83, 1604 Taboada, 2011, Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas, Neuroendocrinology, 93, 40, 10.1159/000322040 Taboada, 2009, Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience, Pituitary, 12, 165, 10.1007/s11102-008-0136-0 Kasuki Jomori de Pinho, 2011, Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53, Neuroendocrinology, 94, 39, 10.1159/000322787 Luque, 2013, A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications, J. Clin. Endocrinol. Metab, 98, 4160, 10.1210/jc.2013-1992 Gahete, 2011, A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance, PLoS ONE, 6, e23302, 10.1371/journal.pone.0023302 Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, 3, 10.1186/gb-2002-3-7-research0034 Cordoba-Chacon, 2010, Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents, Cell. Mol. Life Sci, 67, 1147, 10.1007/s00018-009-0240-y Gadelha, 2013, Novel pathway for somatostatin analogs in patients with acromegaly, Trends Endocrinol. Metab, 24, 238, 10.1016/j.tem.2012.11.007 Saveanu, 2001, Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas, J. Clin. Endocrinol. Metab, 86, 140 Gatto, 2013, beta-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly, Endocrinology, 154, 4715, 10.1210/en.2013-1672 Rocheville, 2000, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers, J. Biol. Chem, 275, 7862, 10.1074/jbc.275.11.7862